[{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase II","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ID1201","moa":"APP\/Alpha-secretase","graph1":"Neurology","graph2":"Phase II","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ildong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ildong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"anti-inflammatory\/analgesic agents (ibuprofen type)","graph1":"Neurology","graph2":"Phase II","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kainos Medicine","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KM-819","moa":"FAS-associated factor 1 (FAF1)","graph1":"Neurology","graph2":"Phase II","graph3":"Kainos Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kainos Medicine \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Kainos Medicine \/ Parexel"},{"orgOrder":0,"company":"Peptron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PT320","moa":"Glucagon (GCG)","graph1":"Neurology","graph2":"Phase II","graph3":"Peptron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peptron \/ Undisclosed"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Hansoh Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Hansoh Pharma"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"Glaceum","sponsor":"Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vutiglabridin","moa":"Mitochondrial function","graph1":"Neurology","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"GV1001","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"GV1001","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GV1001","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tertomotide","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tertomotide","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tertomotide","moa":"peptides","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Epirisone","moa":"Skeletal muscle","graph1":"Neurology","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Pharm Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"JBPOS0101","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Bio-Pharm Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Pharm Solutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Pharm Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Pharm Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JBPOS0101","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Bio-Pharm Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Pharm Solutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Pharm Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DA-9801","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DA-9805","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Immunoglobulin G","moa":"Immunoglobulin G (IgG)","graph1":"Neurology","graph2":"Phase II","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurobiogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"DWP05195","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
